search
drug discovery
Trends
- 1Anthropic Opens Biology Lab in Sign of Broader AI Ambitions●Anthropic's New Biology Lab Signals a Bigger Ambition Than Building AI
Anthropic has established a new biology lab, a move widely read as a signal that the AI company intends to go beyond building models and push into applying artificial intelligence to life sciences research. Commentators say the project suggests Anthropic sees AI-driven biology, including drug discovery and scientific research, as a core part of its future strategy rather than a side project.
- 210x Genomics Starts Global Shipments of Atera Spatial Biology Platform●10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands
10x Genomics has begun worldwide shipments of Atera, a new spatial biology platform the company describes as offering unprecedented capabilities for researchers. The launch gives scientists access to tools for studying tissue biology at higher resolution, and the biotech community is watching closely as the technology reaches labs globally. Early discussion centers on what the platform could mean for drug discovery and disease research.
- 3
Former Genentech artificial intelligence staff have launched Ortet, a new health-focused startup backed with $500 million in funding. The venture aims to apply AI to drug discovery and healthcare development, drawing on the founders' experience at one of biotech's most established companies. The size of the initial backing has made it one of the more notable biotech launches of the moment.
- 4Drug Discovery Shifts From Endpoints to Cellular Data●Better Data, Not Just More Data: Moving Beyond Endpoints and Into Cells for Drug Discovery
A new discussion in the drug discovery field argues that progress depends on better data, not simply more of it, calling for a move beyond traditional endpoint measurements toward richer, cell-level data in early research. The piece suggests that understanding what happens inside cells could improve how promising drug candidates are identified, a debate gaining attention as biotech weighs where to invest in new screening technologies.